ReNeuron
| Company type | Public company |
|---|---|
| LSE: RENE | |
| Industry | Stem cell research & development |
| Founded | 1997 |
| Headquarters | Surrey, England, UK |
Key people | chairman = Trevor Jones |
| Website | reneuron.com |
ReNeuron is a UK-based stem cell research company whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
ReNeuron is testing the effects of neural stem cells on spinal cords for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]
References[edit]
- ^ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- ^ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
External links[edit]
 | This article about a company of the UK is a stub. You can help Wikipedia by expanding it. |